In phase III trials Thrombin Receptor Antagonist Clinical Event Reduction in acute coronary syndrome (TRACER) and Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischaemic Events-TIMI 50 (TRA-2P-TIMI 50) a benefit was noted in specific patient populations such as those with prior myocardial infarction or peripheral arterial disease [153,154]. This evidence concerns the gene F2R and peripheral arterial disease.